During the project, a collection of A. baumannii mutants was generated by individually deleting eleven genes predicted to be involved in c-di-GMP metabolism. Each mutant was validated and subjected to phenotypic assays assessing growth, surface motility, biofilm formation, desiccation tolerance, and antibiotic susceptibility. These traits are critical for understanding the bacteria’s ability to establish infections, resist antibiotic treatment, and survive on hospital surfaces. By linking genetic changes to infection potential and persistence mechanisms, the project directly addresses major challenges in combating A. baumannii in healthcare settings. To better understand how genetic changes affect bacterial behavior, I analyzed the complete set of proteins produced by the bacteria under different conditions, comparing normal strains with genetically modified ones grown both freely and in biofilm communities. Integration of phenotypic, proteomic, and signaling data revealed multiple pathways influenced by c-di-GMP, contributing to biofilm matrix production, membrane remodeling, and stress responses.
Collaborative work was initiated to quantify biofilm polysaccharides in selected mutants, supporting the molecular findings with biochemical validation. Overall, the project successfully built a systems-level understanding of how intracellular signaling networks control clinically relevant traits in A. baumannii, opening new avenues for therapeutic intervention.